Hubble Therapeutics
Hubble Therapeutics LLC is a private Hanover, NH-based biotechnology company developing HUB-101, an AAV-based gene therapy for rare inherited retinal diseases including Leber Congenital Amaurosis type 16 and Superficial Vascular Disease.
- Company typePrivate
- Founded2000
- HeadquartersHanover, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Hubble Therapeutics firmographics
Firmographics- Name
- Hubble Therapeutics
- Legal name
- Hubble Therapeutics LLC
- Website
- https://hubbletx.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Hubble Therapeutics LLC is a private Hanover, NH-based biotechnology company developing HUB-101, an AAV-based gene therapy for rare inherited retinal diseases including Leber Congenital Amaurosis type 16 and Superficial Vascular Disease.
- Ownership category
- akta.pro rank
Hubble Therapeutics industry classification
Industry- Product category
- Ophthalmology Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Ophthalmology Gene Therapies (HLAAACAG)
- akta.pro secondary industries
- Rare Ophthalmology Disorder Therapies (HLAIAIAK), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)
Keywords
Where Hubble Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Hanover
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Hubble Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Gene Therapy Product (HUB-101): Pre-revenue biotechnology company developing a novel gene therapy candidate (HUB-101) for LCA16 and SVD. Revenue will be generated upon successful FDA approval and commercialization of the therapy.
Distribution channels1 record
Marketing channels3 records
Hubble Therapeutics product offering
Product offeringCore offering
Hubble Therapeutics is a pre-clinical biotechnology company developing HUB-101, an AAV (adeno-associated virus) based gene therapy that delivers billions of healthy copies of the KCNJ13 gene to the Retinal Pigment Epithelium (RPE) layer to restore Kir7.1 ion channel function. The lead candidate targets Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), two rare inherited pediatric blindness disorders caused by KCNJ13 gene mutations.
Product overview
Hubble Therapeutics is a patient-focused biotechnology company developing a single gene therapy product, HUB-101, for the treatment of Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD). The company operates as a lean biotech with one lead candidate in the pipeline, having received FDA Rare Pediatric Disease Designation and Orphan Disease Designation for HUB-101, and has partnered with Andelyn Biosciences and Virscio for manufacturing and IND-enabling studies.
Differentiator
Problem solved
Functional benefit
Products and services
- HUB-101 HUB-101 is an AAV-based gene therapy candidate that delivers billions of healthy copies of the KCNJ13 gene directly to the Retinal Pigment Epithelium (RPE) layer to restore Kir7.1 ion channel function and treat Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD). It is intended as a single one-time treatment addressing the genetic root cause of these rare inherited pediatric eye disorders.
Quantifiable outcome
- Phase I/II clinical trials planned to begin in 2026
Companies that use Hubble Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Hubble Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Hubble Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Andelyn BiosciencescoreAndelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), was selected to manufacture clinical grade AAV using its suspension AAV Curator Platform for the treatment of LCA16. Andelyn will optimize and scale-up the HUB-101 process, generate GMP-grade plasmids, and produce GMP vectors containing normal copies of the KCNJ13 gene for Phase 1/2 clinical trials.
- VirsciocoreVirscio partnered with Hubble Therapeutics for manufacturing and IND-enabling studies supporting the HUB-101 gene therapy development program for LCA16.
- Wisconsin Alumni Research Foundation (WARF)coreThe HUB-101 gene therapy technology was developed by Dr. Bikash Pattnaik at the University of Wisconsin-Madison and licensed from the Wisconsin Alumni Research Foundation. This licensing agreement provides Hubble Therapeutics rights to the proprietary gene therapy technology for KCNJ13 gene delivery.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Hubble Therapeutics competitors and assessment
Company assessmentDirect peers
- Spark Therapeutics: Developer of Luxturna, the first FDA-approved AAV gene therapy for an inherited retinal disease (RPE65 mutation/LCA2). Now part of Roche, Spark is the closest analog in ocular AAV gene therapy targeting Leber Congenital Amaurosis and sets the regulatory and commercial benchmark for Hubble's LCA16 program.
- Editas Medicine: Clinical-stage gene editing company that has pursued LCA10 (a different LCA subtype) with EDIT-101, an AAV-delivered CRISPR therapy. Directly comparable in developing ocular gene therapy for inherited retinal dystrophies within the LCA family.
- MeiraGTx Holdings: Clinical-stage gene therapy company with multiple AAV-based programs targeting inherited retinal diseases (e.g., X-linked retinitis pigmentosa, achromatopsia). Comparable in modality (AAV gene therapy), therapeutic area (inherited retinal disease), and stage (early clinical).
- 4D Molecular Therapeutics: Clinical-stage AAV gene therapy company with ophthalmology programs (e.g., choroideremia, RPE65-related disease). Comparable in deploying next-generation AAV vectors for inherited retinal diseases.
- Applied Genetic Technologies Corp (AGTC): Clinical-stage gene therapy company developing AAV-based treatments for rare inherited retinal diseases (e.g., X-linked retinitis pigmentosa, achromatopsia). Highly comparable in modality, indication space, and stage of development.
Emerging players
- Beacon Therapeutics: Emerging ocular gene therapy company developing AAV-based treatments for X-linked retinitis pigmentosa and other inherited retinal diseases. Comparable focus area in inherited retinal dystrophies, though focused on different genetic targets.
- Nanoscope Therapeutics: Clinical-stage gene therapy company developing optogenetic therapies for retinal degenerative diseases including retinitis pigmentosa. Comparable in targeting inherited retinal blindness with a one-time gene therapy approach, though using a different mechanism.
- ProQR Therapeutics: Clinical-stage RNA editing company developing therapies for inherited retinal diseases (e.g., Leber Congenital Amaurosis, Usher syndrome, retinitis pigmentosa). Comparable in targeting LCA and other inherited retinal diseases through genetic approaches, though using RNA rather than AAV gene replacement.
Broad incumbents
- REGENXBIO: Clinical-stage AAV gene therapy company with a broad pipeline including ocular programs (RGX-314 for wet AMD with AbbVie). Comparable in AAV platform technology and ophthalmology focus, though at later stage and broader scope.
- Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based treatments for ocular diseases (wet AMD, diabetic retinopathy). Comparable in AAV ocular delivery and rare ophthalmology positioning.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Hubble Therapeutics social profiles
Digital presenceHubble Therapeutics compliance and trust
Trust signalCompliance2 records
Hubble Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hubble Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Hubble Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hubble Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hubble Therapeutics
What does Hubble Therapeutics do?
Hubble Therapeutics is a pre-clinical biotechnology company developing HUB-101, an AAV (adeno-associated virus) based gene therapy that delivers billions of healthy copies of the KCNJ13 gene to the Retinal Pigment Epithelium (RPE) layer to restore Kir7.1 ion channel function. The lead candidate targets Leber Congenital Amaurosis Type 16 (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), two rare inherited pediatric blindness disorders caused by KCNJ13 gene mutations.
Is Hubble Therapeutics a public or private company?
Hubble Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Hubble Therapeutics founded?
Hubble Therapeutics was founded in 2000. It employs 1 to 10 people.
Where is Hubble Therapeutics based?
Hubble Therapeutics is headquartered in Hanover, United States, in the North America region.
How does Hubble Therapeutics make money?
One revenue line is on record: gene Therapy Product (HUB-101).
Who are Hubble Therapeutics's main competitors?
Direct peers on record are Spark Therapeutics, Editas Medicine, MeiraGTx Holdings, 4D Molecular Therapeutics and Applied Genetic Technologies Corp (AGTC). Emerging players are Beacon Therapeutics, Nanoscope Therapeutics and ProQR Therapeutics. Broad incumbents are REGENXBIO and Adverum Biotechnologies.
Does Hubble Therapeutics have an API?
No public API is recorded for Hubble Therapeutics.
What industry is Hubble Therapeutics in?
Hubble Therapeutics's product category is Ophthalmology Gene Therapy. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAIAIAK, Rare Ophthalmology Disorder Therapies. Its NAICS code is 541714 and its SIC code is 3851.